drugset / Trial / NCT00814385
Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04
Phase 1/2
Completed
606 enrolled
University Hospitals, Leicester
Medical Research Council · collabNational Institute of Biological Standards and Control · collabNovartis · collabPublic Health England · collab
RandomizedSingle-groupDouble-blind
Summary
This study focuses on pre-pandemic priming of man against H5 influenza with the goal of mounting a robust antibody response to small quantities of vaccine either before or during an H5 pandemic.
Timeline
- Start
- 2008-11
- Primary completion
- 2013-09
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflunov | Vaccine | 3.75 ug | Intramuscular |
| Comparator | Aflunov | Vaccine | 7.5 ug | Intramuscular |